At present, there are several Gal3 inhibitors in clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), liver cirrhosis, portal hypertension or tumors36,51,52, indicating that Gal3 is a druggable target. The gene discussed is LGALS3; the disease is liver disorder.